ELV LEGAL NOTICE: Lose Money when Elevance Health, Inc. Stock Plummeted 11%? Contact BFA Law by the July 11 Court Deadline (NYSE:ELV)

Core Viewpoint - A lawsuit has been filed against Elevance Health, Inc. and certain senior executives for potential violations of federal securities laws, specifically related to the management of Medicaid benefits and the subsequent financial impact on the company [1][2]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of Indiana, titled Miller v. Elevance Health, Inc., et al., No. 25-cv-0092, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [2]. - Investors have until July 11, 2025, to request to be appointed to lead the case [2]. Group 2: Company Operations and Allegations - Elevance Health provides health insurance plans, including contracts with states to administer Medicaid benefits, which were paused during COVID-19 and resumed in 2023 [3]. - The company claimed to be monitoring cost trends related to Medicaid redetermination and believed its negotiated rates were adequate for the risk profiles of Medicaid patients [4]. Group 3: Financial Impact and Stock Performance - The redetermination process led to a significant increase in the acuity and utilization of Elevance's Medicaid members, which was not reflected in the company's financial guidance for 2024 [5]. - Following an announcement on July 17, 2024, regarding increased Medicaid utilization, Elevance's stock price fell by $32.21, nearly 6%, from $553.14 to $520.93 per share [6]. - On October 17, 2024, Elevance reported Q3 2024 results, missing consensus EPS expectations by $1.33, or 13.7%, due to elevated medical costs in its Medicaid business, resulting in a stock price decline of $52.61, nearly 11%, from $496.96 to $444.35 per share [7].